Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's choice to lead Medicare and Medicaid services. But this could mean a potential ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

People tend to like their Medicare Advantage plans — until they don’t. Consider the case of Rose LaChapelle, who says the Medicare Advantage plan that was supposed to provide care for her 92 ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the press and the medical community for its ability to trigger profound weight loss.

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

Share on Pinterest Ozempic (semaglutide) is a medication approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. Because Ozempic has been shown to boost weight loss in people ...

Ozempic, known medically as semaglutide, was originally designed to help adult patients with type 2 diabetes control their blood sugar. However, this drug — and a host of others in this class of ...